Aug 08, 2024 4:05 PM
Second Quarter 2024 Highlights
All comparisons are to the quarter ended
“Given the health of our pipeline and clear line of sight for the remainder of the year, we are reiterating guidance and are enthusiastic about our future outlook,” concluded Fowler.
Financial Guidance
For the third quarter of 2024,
For the full year 2024,
Conference Call
About
We are a trusted partner to more than 1,500 healthcare organizations with a broad range of technology-first solutions that address the unique needs and challenges of diverse communities, promoting equitable access to quality care and fostering positive outcomes.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified generally by the use of forward-looking terminology and words such as “expects,” “anticipates,” “estimates,” “believes,” “predicts,” “intends,” “plans,” “potential,” “may,” “continue,” “should,” “will” and words of comparable meaning. Without limiting the generality of the preceding statement, all statements in this press release relating to the Company’s future financial and operational results are forward-looking statements. We caution investors that any such forward-looking statements are only predictions and are not guarantees of future performance. Certain risks, uncertainties and other factors may cause actual results to differ materially from those projected in the forwardlooking statements. Such factors may include: saturation of our target market and hospital consolidations; unfavorable economic or market conditions that may cause a decline in spending for information technology and services; significant legislative and regulatory uncertainty in the healthcare industry; exposure to liability for failure to comply with regulatory requirements; pandemics and other public health crises and related economic disruptions; transition to a subscription-based recurring revenue model and modernization of our technology; competition with companies that have greater financial, technical and marketing resources than we have; potential future acquisitions that may be expensive, time consuming, and subject to other inherent risks; our ability to attract and retain qualified client service and support personnel; disruption from periodic restructuring of our sales force; potential delay in the development of markets for our RCM service offering; potential inability to properly manage growth in new markets we may enter; potential disruption of our business due to our ongoing implementation of a new enterprise resource planning software solution; exposure to numerous and often conflicting laws, regulations, policies, standards or other requirements through our international business activities; potential litigation against us; our reliance on an international workforce which exposes us to various business disruptions; our utilization of artificial intelligence, which could expose us to liability or adversely affect our business if we cannot compete effectively with others using artificial intelligence; potential failure to develop new products or enhance current products that keep pace with market demands; failure of our products to function properly resulting in claims for medical and other losses; breaches of security and viruses in our systems resulting in customer claims against us and harm to our reputation; failure to maintain customer satisfaction through new product releases free of undetected errors or problems; failure to convince customers to migrate to current or future releases of our products; failure to maintain our margins and service rates; increase in the percentage of total revenues represented by service revenues, which have lower gross margins; exposure to liability in the event we provide inaccurate claims data to payors; exposure to liability claims arising out of the licensing of our software and provision of services; dependence on licenses of rights, products and services from third parties; misappropriation of our intellectual property rights and potential intellectual property claims and litigation against us; interruptions in our power supply and/or telecommunications capabilities, including those caused by natural disaster; potential inability to secure additional financing on favorable terms to meet our future capital needs; our substantial indebtedness, and our ability to incur additional indebtedness in the future; pressures on cash flow to service our outstanding debt; restrictive terms of our credit agreement on our current and future operations; changes in and interpretations of financial accounting matters that govern the measurement of our performance; significant charges to earnings if our goodwill or intangible assets become impaired; fluctuations in quarterly financial performance due to, among other factors, timing of customer installations; volatility in our stock price; failure to maintain effective internal control over financial reporting; inherent limitations in our internal control over financial reporting; vulnerability to significant damage from natural disasters; market risks related to interest rate changes; potential material adverse effects due to macroeconomic conditions, including bank failures or changes in related regulation; and other risk factors described from time to time in our public releases and reports filed with the
Condensed Consolidated Statements of Income | |||||||||||||||
(In '000s, except per share data) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended |
Six Months Ended |
||||||||||||||
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
||||
Revenues | |||||||||||||||
RCM | $ |
54,108 |
|
$ |
47,760 |
|
$ |
107,146 |
|
$ |
96,391 |
|
|||
EHR |
|
30,622 |
|
|
36,862 |
|
|
60,831 |
|
|
74,464 |
|
|||
Total revenues |
|
84,730 |
|
|
84,622 |
|
|
167,977 |
|
|
170,855 |
|
|||
Expenses | |||||||||||||||
Costs of revenue (exclusive of amortization and depreciation) | |||||||||||||||
RCM |
|
30,269 |
|
|
27,119 |
|
|
59,866 |
|
|
54,302 |
|
|||
EHR |
|
13,073 |
|
|
17,014 |
|
|
25,237 |
|
|
34,008 |
|
|||
Total costs of revenue (exclusive of amortization and depreciation) |
|
43,342 |
|
|
44,133 |
|
|
85,103 |
|
|
88,310 |
|
|||
Product development |
|
8,207 |
|
|
8,769 |
|
|
18,894 |
|
|
17,121 |
|
|||
Sales and marketing |
|
7,815 |
|
|
8,132 |
|
|
14,408 |
|
|
15,089 |
|
|||
General and administrative |
|
18,878 |
|
|
19,057 |
|
|
38,274 |
|
|
33,510 |
|
|||
Amortization |
|
9,107 |
|
|
5,858 |
|
|
14,975 |
|
|
11,341 |
|
|||
Depreciation |
|
400 |
|
|
579 |
|
|
800 |
|
|
1,095 |
|
|||
Total expenses |
|
87,749 |
|
|
86,528 |
|
|
172,454 |
|
|
166,466 |
|
|||
Operating income (loss) |
|
(3,019 |
) |
|
(1,906 |
) |
|
(4,477 |
) |
|
4,389 |
|
|||
Other income (expense): | |||||||||||||||
Other income |
|
91 |
|
|
78 |
|
|
1,514 |
|
|
346 |
|
|||
Interest expense |
|
(4,242 |
) |
|
(2,664 |
) |
|
(8,315 |
) |
|
(5,334 |
) |
|||
Total other expense |
|
(4,151 |
) |
|
(2,586 |
) |
|
(6,801 |
) |
|
(4,988 |
) |
|||
Loss before taxes |
|
(7,170 |
) |
|
(4,492 |
) |
|
(11,278 |
) |
|
(599 |
) |
|||
Income tax benefit |
|
(2,121 |
) |
|
(1,655 |
) |
|
(3,713 |
) |
|
(846 |
) |
|||
Net income (loss) | $ |
(5,049 |
) |
$ |
(2,837 |
) |
$ |
(7,565 |
) |
$ |
247 |
|
|||
Net income (loss) per common share—basic | $ |
(0.34 |
) |
$ |
(0.20 |
) |
$ |
(0.51 |
) |
$ |
0.02 |
|
|||
Net income (loss) per common share—diluted | $ |
(0.34 |
) |
$ |
(0.20 |
) |
$ |
(0.51 |
) |
$ |
0.02 |
|
|||
Weighted average shares outstanding used in per common share computations: | |||||||||||||||
Basic |
|
14,313 |
|
|
14,200 |
|
|
14,273 |
|
|
14,168 |
|
|||
Diluted |
|
14,313 |
|
|
14,200 |
|
|
14,273 |
|
|
14,168 |
|
Condensed Consolidated Balance Sheets | |||||||
(In '000s, except per share data) | |||||||
(Unaudited) |
|||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ |
7,709 |
|
$ |
3,848 |
|
|
Accounts receivable, net of allowance for expected credit losses of |
|
59,603 |
|
|
59,723 |
|
|
Financing receivables, current portion (net of allowance for expected credit losses of |
|
4,137 |
|
|
3,997 |
|
|
Inventories |
|
793 |
|
|
475 |
|
|
Prepaid income taxes |
|
2,307 |
|
|
1,628 |
|
|
Prepaid expenses and other |
|
17,034 |
|
|
15,807 |
|
|
Assets of held for sale disposal group |
|
- |
|
|
25,977 |
|
|
Total current assets |
|
91,583 |
|
|
111,455 |
|
|
Property & equipment, net |
|
8,479 |
|
|
8,974 |
|
|
Software development costs, net |
|
39,741 |
|
|
39,139 |
|
|
Operating lease assets |
|
3,861 |
|
|
5,192 |
|
|
Financing receivables, net of current portion (net of allowance for expected credit losses of |
|
607 |
|
|
1,226 |
|
|
Other assets, net of current portion |
|
8,337 |
|
|
7,314 |
|
|
Intangible assets, net |
|
82,960 |
|
|
89,213 |
|
|
|
172,573 |
|
|
171,909 |
|
||
Deferred tax assets |
|
4,146 |
|
|
- |
|
|
Total assets | $ |
412,287 |
|
$ |
434,422 |
|
|
Liabilities & Stockholders' Equity | |||||||
Current liabilities | |||||||
Accounts payable | $ |
15,854 |
|
$ |
10,133 |
|
|
Current portion of long-term debt |
|
3,074 |
|
|
3,141 |
|
|
Deferred revenue |
|
9,842 |
|
|
8,677 |
|
|
Accrued vacation |
|
5,458 |
|
|
5,410 |
|
|
Liabilities of held for sale disposal group |
|
- |
|
|
977 |
|
|
Other accrued liabilities |
|
17,481 |
|
|
19,892 |
|
|
Total current liabilities |
|
51,709 |
|
|
48,230 |
|
|
Long-term debt, net of current portion |
|
176,964 |
|
|
195,270 |
|
|
Operating lease liabilities, net of current portion |
|
2,512 |
|
|
3,074 |
|
|
Deferred tax liabilities |
|
- |
|
|
1,230 |
|
|
Total liabilities |
|
231,185 |
|
|
247,804 |
|
|
Stockholders' Equity | |||||||
Common stock, |
|
15 |
|
|
15 |
|
|
|
(17,434 |
) |
|
(17,075 |
) |
||
Accumulated other comprehensive gain |
|
108 |
|
|
- |
|
|
Additional paid-in capital |
|
197,846 |
|
|
195,546 |
|
|
Retained earnings |
|
567 |
|
|
8,132 |
|
|
Total stockholders' equity |
|
181,102 |
|
|
186,618 |
|
|
Total liabilities and stockholders' equity | $ |
412,287 |
|
$ |
434,422 |
|
Condensed Consolidated Statements of Cash Flows | |||||||
(In '000s) | |||||||
(Unaudited) | |||||||
Six Months Ended |
|||||||
|
2024 |
|
|
2023 |
|
||
Operating activities: | |||||||
Net income (loss) | $ |
(7,565 |
) |
$ |
247 |
|
|
Adjustments to net income (loss): | |||||||
Provision for credit losses |
|
358 |
|
|
181 |
|
|
Deferred taxes |
|
(5,224 |
) |
|
(1,533 |
) |
|
Stock-based compensation |
|
2,300 |
|
|
1,124 |
|
|
Depreciation |
|
800 |
|
|
1,095 |
|
|
Gain on sale of business |
|
(1,250 |
) |
|
- |
|
|
Amortization of acquisition-related intangibles |
|
6,253 |
|
|
8,029 |
|
|
Amortization of software development costs |
|
8,722 |
|
|
3,312 |
|
|
Amortization of deferred finance costs |
|
213 |
|
|
180 |
|
|
Non-cash operating lease costs |
|
897 |
|
|
1,211 |
|
|
Loss on disposal of property and equipment |
|
- |
|
|
117 |
|
|
Changes in operating assets and liabilities: | |||||||
Accounts receivable |
|
654 |
|
|
(3,806 |
) |
|
Financing receivables |
|
506 |
|
|
940 |
|
|
Inventories |
|
(318 |
) |
|
(178 |
) |
|
Prepaid expenses and other |
|
1,502 |
|
|
(2,017 |
) |
|
Accounts payable |
|
5,750 |
|
|
7,448 |
|
|
Deferred revenue |
|
1,769 |
|
|
(1,705 |
) |
|
Operating lease liabilities |
|
(583 |
) |
|
(1,067 |
) |
|
Other liabilities |
|
(2,375 |
) |
|
(2,278 |
) |
|
Prepaid income taxes |
|
(679 |
) |
|
(1,110 |
) |
|
Net cash provided by operating activities |
|
11,730 |
|
|
10,190 |
|
|
Investing activities: | |||||||
Purchase of business, net of cash acquired |
|
(664 |
) |
|
- |
|
|
Sale of business, net of cash and cash equivalents sold |
|
21,410 |
|
|
- |
|
|
Investment in software development |
|
(9,324 |
) |
|
(12,143 |
) |
|
Purchases of property and equipment |
|
(306 |
) |
|
(72 |
) |
|
Net cash provided by (used in) investing activities |
|
11,116 |
|
|
(12,215 |
) |
|
Financing activities: | |||||||
|
(358 |
) |
|
(2,532 |
) |
||
Payments of long-term debt principal |
|
(5,750 |
) |
|
(1,750 |
) |
|
Proceeds from revolving line of credit |
|
21,072 |
|
|
11,602 |
|
|
Payments of revolving line of credit |
|
(33,379 |
) |
|
(5,000 |
) |
|
Debt issuance cots |
|
(529 |
) |
|
- |
|
|
Net cash provided by (used in) financing activities |
|
(18,944 |
) |
|
2,320 |
|
|
Increase in cash and cash equivalents |
|
3,902 |
|
|
295 |
|
|
Change in cash and cash equivalents included in assets sold |
|
(41 |
) |
||||
Cash and cash equivalents, beginning of period |
|
3,848 |
|
|
6,951 |
|
|
Cash and cash equivalents, end of period | $ |
7,709 |
|
$ |
7,246 |
|
Consolidated Bookings | ||||||||||
(In '000s) | ||||||||||
(Unaudited) (Non-GAAP) | ||||||||||
Three Months Ended |
Six Months Ended |
|||||||||
In '000s | 2024 |
2023 (3) |
2024 |
2023 (3) |
||||||
RCM(1) | $ |
13,458 |
$ |
13,648 |
$ |
27,849 |
$ |
25,748 |
||
EHR(2) |
|
9,832 |
|
7,322 |
|
19,010 |
|
15,069 |
||
Total | $ |
23,290 |
$ |
20,970 |
$ |
46,859 |
$ |
40,817 |
||
(1) |
Generally calculated as the total contract price (for non-recurring, project-related amounts) and annualized contract value (for recurring amounts). |
|||||||||
(2) |
Generally calculated as the total contract price (for system sales) and annualized contract value (for support) for perpetual license system sales and total contract price for SaaS sales. |
|||||||||
(3) |
Adjustment was made to the 2023 bookings, due to 3rd |
Bookings Composition | ||||||||||
(In '000s, except per share data) | ||||||||||
(Unaudited) (Non-GAAP) | ||||||||||
Three Months Ended |
Six Months Ended |
|||||||||
2024 |
2023 (3) |
2024 |
2023 (3) |
|||||||
RCM | ||||||||||
Net new(1) | $ |
6,453 |
$ |
3,395 |
$ |
15,446 |
$ |
9,749 |
||
Cross-sell(1) |
|
7,004 |
|
10,253 |
|
12,402 |
|
15,999 |
||
EHR | ||||||||||
Non-subscription sales(2) |
|
4,084 |
|
4,458 |
|
7,534 |
|
10,506 |
||
Subscription revenue(3) |
|
5,749 |
|
2,864 |
|
11,477 |
|
4,563 |
||
Total | $ |
23,290 |
$ |
20,970 |
$ |
46,859 |
$ |
40,817 |
||
(1) |
“Net new” represents bookings from outside the Company’s core EHR client base, and “Cross-sell” represents bookings from existing EHR customers. In each case, such bookings are generally comprised of recurring revenues to be recognized ratably over a one-year period and an average timeframe for commencement of bookings-to-revenue conversion of four to six months following contract execution. |
|||||||||
(2) |
Represents nonrecurring revenues that generally exhibit a timeframe for bookings-to-revenue conversion of five to six months following contract execution. |
|||||||||
(3) |
Represents recurring revenues to be recognized on a monthly basis over a weighted-average contract period of five years, with a start date in the next 12 months and an average timeframe for commencement of bookings-to-revenue conversion of five to six months following contract execution. |
Adjusted EBITDA - by Segment | |||||||||
(In '000s) | |||||||||
(Unaudited) (Non-GAAP) | |||||||||
Three Months Ended |
Six Months Ended |
||||||||
In '000s | 2024 |
2023 |
2024 |
2023 |
|||||
RCM | $ |
7,804 |
$ |
5,682 |
$ |
14,202 |
$ |
13,580 |
|
EHR |
|
4,770 |
|
5,545 |
|
7,826 |
|
12,289 |
|
Total | $ |
12,574 |
$ |
11,227 |
$ |
22,028 |
$ |
25,869 |
Reconciliation of Non-GAAP Financial Measures | |||||||||||||||
(In '000s) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended |
Six Months Ended |
||||||||||||||
Adjusted EBITDA: |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
|||
Net income (loss), as reported | $ |
(5,049 |
) |
$ |
(2,837 |
) |
$ |
(7,565 |
) |
$ |
247 |
|
|||
Net Income Margin |
|
(6.0 |
%) |
|
(3.4 |
%) |
|
(4.5 |
%) |
|
0.1 |
% |
|||
Depreciation expense |
|
400 |
|
|
597 |
|
|
800 |
|
|
1,095 |
|
|||
Amortization of software development costs |
|
5,980 |
|
|
1,826 |
|
|
8,722 |
|
|
3,312 |
|
|||
Amortization of acquisition-related intangibles |
|
3,126 |
|
|
4,014 |
|
|
6,253 |
|
|
8,029 |
|
|||
Stock-based compensation |
|
1,501 |
|
|
(123 |
) |
|
2,300 |
|
|
1,124 |
|
|||
Severance and other non-recurring charges |
|
4,586 |
|
|
6,819 |
|
|
8,430 |
|
|
7,920 |
|
|||
Interest expense |
|
4,151 |
|
|
2,586 |
|
|
8,051 |
|
|
4,988 |
|
|||
Gain on sale of AHT |
|
- |
|
|
- |
|
|
(1,250 |
) |
|
- |
|
|||
Provision (benefit) for income taxes |
|
(2,121 |
) |
|
(1,655 |
) |
|
(3,713 |
) |
|
(846 |
) |
|||
Total Adjusted EBITDA | $ |
12,574 |
|
$ |
11,227 |
|
$ |
22,028 |
|
$ |
25,869 |
|
|||
Adjusted EBITDA Margin |
|
14.8 |
% |
|
13.3 |
% |
|
13.1 |
% |
|
15.1 |
% |
Reconciliation of Non-GAAP Financial Measures | |||||||||||||||
(In '000s, except per share data) | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended |
Six Months Ended |
||||||||||||||
Non-GAAP Net Income and Non-GAAP EPS: |
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
|||
Net income (loss), as reported | $ |
(5,049 |
) |
$ |
(2,837 |
) |
$ |
(7,565 |
) |
$ |
247 |
|
|||
Pre-tax adjustments for Non-GAAP EPS: | |||||||||||||||
Amortization of acquisition-related intangible assets |
|
3,126 |
|
|
4,014 |
|
|
6,253 |
|
|
8,029 |
|
|||
Stock-based compensation |
|
1,501 |
|
|
(123 |
) |
|
2,300 |
|
|
1,124 |
|
|||
Severance and other nonrecurring charges |
|
4,586 |
|
|
6,819 |
|
|
8,430 |
|
|
7,920 |
|
|||
Non-cash interest expense |
|
107 |
|
|
90 |
|
|
213 |
|
|
180 |
|
|||
After-tax adjustments for Non-GAAP EPS: | |||||||||||||||
Tax-effect of pre-tax adjustments, at 21% |
|
(1,957 |
) |
|
(2,269 |
) |
|
(3,611 |
) |
|
(3,623 |
) |
|||
Tax shortfall (windfall) from stock-based compensation |
|
4 |
|
|
7 |
|
|
113 |
|
|
57 |
|
|||
Non-GAAP net income | $ |
2,318 |
|
$ |
5,701 |
|
$ |
6,133 |
|
$ |
13,934 |
|
|||
Weighted average shares outstanding, diluted |
|
14,313 |
|
|
14,200 |
|
|
14,273 |
|
|
14,168 |
|
|||
Non-GAAP EPS | $ |
0.16 |
|
$ |
0.40 |
|
$ |
0.43 |
|
$ |
0.98 |
|
Electronic Health Record (EHR) Revenue Composition | |||||||||||
(In '000s) | |||||||||||
(Unaudited) | |||||||||||
Three Months Ended |
Six Months Ended |
||||||||||
2024 |
2023 |
2024 |
2023 |
||||||||
Recurring revenues - EHR | |||||||||||
Acute Care EHR | $ |
26,666 |
$ |
30,013 |
$ |
54,160 |
$ |
59,353 |
|||
Post-acute Care EHR |
|
- |
|
3,729 |
|
582 |
|
7,636 |
|||
Total recurring revenues - EHR |
|
26,666 |
|
33,742 |
|
54,742 |
|
66,989 |
|||
Non-recurring revenues - EHR | |||||||||||
Acute Care EHR |
|
3,956 |
|
2,775 |
|
6,008 |
|
6,750 |
|||
Post-acute Care EHR |
|
- |
|
345 |
|
81 |
|
725 |
|||
Total non-recurring revenues - EHR |
|
3,956 |
|
3,120 |
|
6,089 |
|
7,475 |
|||
Total EHR revenues | $ |
30,622 |
$ |
36,862 |
$ |
60,831 |
$ |
74,464 |
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with accounting principles generally accepted in
As such, to supplement the GAAP information provided, we present in this press release and during the live webcast discussing our financial results the following non-GAAP- financial measures: Adjusted EBITDA, Adjusted EBITDA Margin, Non-GAAP net income, and Non-GAAP earnings per share (“EPS”).
We calculate each of these non-GAAP financial measures as follows:
Certain of the items excluded or adjusted to arrive at these non-GAAP financial measures are described below:
Management considers these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance. In addition, management may use Adjusted EBITDA, Non-GAAP net income and/or Non-GAAP EPS to measure the achievement of performance objectives under the Company’s stock and cash incentive programs. Note, however, that these non-GAAP financial measures are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not alternatives for measures of financial performance prepared in accordance with GAAP and may be different from similarly titled non-GAAP measures presented by other companies, limiting their usefulness as comparative measures. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Additionally, there is no certainty that we will not incur expenses in the future that are similar to those excluded in the calculations of the non-GAAP financial measures presented in this press release. Investors and potential investors are encouraged to review the “Unaudited Reconciliation of Non-GAAP Financial Measures” above.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808342375/en/
Investor Relations Contact
TBRGIR@westwicke.com
Media Contact
Chief Marketing Officer
Tracey.schroeder@trubridge.com
(251) 639-8100
Source: